BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15372361)

  • 1. Metformin ameliorates treatment of obese type 2 diabetic patients with mental retardation; its effects on eating behavior and serum leptin levels.
    Komori T; Yoshida F; Nakamura J; Miyazaki S; Miura H; Iguchi A
    Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):422-8. PubMed ID: 15372361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
    Fritsche A; Schmülling RM; Häring HU; Stumvoll M
    Acta Diabetol; 2000 Mar; 37(1):13-8. PubMed ID: 10928231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
    Nar A; Gedik O
    Acta Diabetol; 2009 Jun; 46(2):113-8. PubMed ID: 18839053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum leptin concentrations in children with type 1 diabetes mellitus: relationship to body mass index, insulin dose, and glycemic control.
    Soliman AT; Omar M; Assem HM; Nasr IS; Rizk MM; El Matary W; El Alaily RK
    Metabolism; 2002 Mar; 51(3):292-6. PubMed ID: 11887162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum leptin and its relationship with metabolic variables in Arabs with type 2 diabetes mellitus.
    Al-Shoumer KA; Al-Asousi AA; Doi SA; Vasanthy BA
    Ann Saudi Med; 2008; 28(5):367-70. PubMed ID: 18779635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
    Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
    Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
    Li S; Li H; Wang R; Zhang JP
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(15):3490-3495. PubMed ID: 28829491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
    Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.